Recent debates about drug pricing have tended to focus on manufacturers and patients, but Doug Collins is among the few legislators looking at the middlemen.

Collins, a Republican congressman from Georgia, railed against the country’s three major pharmacy benefit managers in an interview with STAT, expressing his desire for a drug-pricing debate that centers on what he views as the true power centers instead of  “Pharma bro” and the push to allow drug-price negotiation under Medicare Part D.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy